دورية أكاديمية
Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III-trial AGITG-MAX.
| العنوان: | Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III-trial AGITG-MAX. |
|---|---|
| المؤلفون: | van Dijk E; Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, VU University Medical Center, Amsterdam, The Netherlands., van Werkhoven E; Biometrics Department, Erasmus Medical Center, Rotterdam, The Netherlands., Asher R; Department of Biostatistics, NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia., Mooi JK; Olivia Newton-John Cancer Research Institute, Heidelberg, Australia.; Department of Medicine, University of Melbourne, Melbourne, Australia.; Peter MacCallum Cancer Institute, Melbourne, Australia., Espinoza D; Department of Biostatistics, NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia., van Essen HF; Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, VU University Medical Center, Amsterdam, The Netherlands., van Tinteren H; Trial and Datacenter, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., van Grieken NCT; Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, VU University Medical Center, Amsterdam, The Netherlands., Punt CJA; Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.; Department of Epidemiology, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands., Tebbutt NC; Department of Medical Oncology, Austin Health, Heidelberg, Australia.; Department of Surgery, University of Melbourne, Melbourne, Australia., Ylstra B; Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, VU University Medical Center, Amsterdam, The Netherlands. |
| المصدر: | International journal of cancer [Int J Cancer] 2022 Oct 01; Vol. 151 (7), pp. 1166-1174. Date of Electronic Publication: 2022 May 23. |
| نوع المنشور: | Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0042124 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0215 (Electronic) Linking ISSN: 00207136 NLM ISO Abbreviation: Int J Cancer Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 1995- : New York, NY : Wiley-Liss Original Publication: 1966-1984 : Genève : International Union Against Cancer |
| مواضيع طبية MeSH: | Colonic Neoplasms*/genetics , Colorectal Neoplasms*/drug therapy , Colorectal Neoplasms*/genetics , Colorectal Neoplasms*/pathology , Rectal Neoplasms*/drug therapy, Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bevacizumab/therapeutic use ; Chromosome Deletion ; Chromosomes ; Disease-Free Survival ; Fluorouracil/therapeutic use ; Humans ; Retrospective Studies |
| مستخلص: | The VEGF-A monoclonal antibody bevacizumab is currently recommended for first-line treatment of all metastatic colorectal cancer (mCRC) patients. Cost-benefit ratio and side-effects however necessitate patient selection. A large retrospective yet nonrandomized study showed that patients with loss of chromosome 18q11.2-q12.1 in the tumor and treated with bevacizumab have 3 months improved median progression-free (PFS) and overall survival (OS) benefit compared to patients without this loss and/or treatment modality. Implementation for loss of chromosome 18q11.2-q12.1 as a marker in clinical practice mandates evidence in a randomized controlled trial for bevacizumab. Of the trials with randomization of chemotherapy vs chemotherapy with bevacizumab, the AGITG-MAX trial was the only one with tumor materials available. Chromosome 18q11.2-q12.1 copy number status was measured for 256 AGITG-MAX trial patients and correlated with PFS according to a predefined analysis plan with marker-treatment interaction as the primary end-point. Chromosome 18q11.2-q12.1 losses were detected in 71% of patients (181/256) characteristic for mCRC. Consistent with the nonrandomized study, significant PFS benefit of bevacizumab was observed in patients with chromosome 18q11.2-q12.1 loss (P = .009), and not in patients without 18q loss (P = .67). Although significance for marker-treatment interaction was not reached (P (© 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.) |
| References: | Bioinformatics. 2009 Jul 15;25(14):1754-60. (PMID: 19451168) N Engl J Med. 2004 Jun 3;350(23):2335-42. (PMID: 15175435) Eur J Cancer. 2019 Jan;106:37-44. (PMID: 30476731) Clin Colorectal Cancer. 2019 Jun;18(2):141-148. (PMID: 30713134) Sci Rep. 2020 Jun 17;10(1):9778. (PMID: 32555399) Nucleic Acids Res. 2021 Dec 2;49(21):12007-12016. (PMID: 34230973) Acta Oncol. 2020 Apr;59(4):395-403. (PMID: 32048563) Clin Pharmacol Ther. 2015 Jul;98(1):34-46. (PMID: 25868461) Cancer Treat Rev. 2021 Jun;97:102202. (PMID: 33838596) J Clin Oncol. 2011 Jul 1;29(19):2675-82. (PMID: 21646616) Am J Clin Oncol. 1982 Dec;5(6):649-55. (PMID: 7165009) Clin Cancer Res. 2018 Sep 15;24(18):4365-4370. (PMID: 29743182) Nat Rev Clin Oncol. 2021 Aug;18(8):506-525. (PMID: 33864051) Nat Med. 2015 Nov;21(11):1350-6. (PMID: 26457759) J Clin Oncol. 2012 Feb 20;30(6):608-15. (PMID: 22253466) Ann Oncol. 2018 Nov 1;29(11):2240-2246. (PMID: 30247524) J Clin Oncol. 2010 Jul 1;28(19):3191-8. (PMID: 20516443) Oncotarget. 2017 Jun 27;8(26):42949-42961. (PMID: 28487489) JAMA. 2011 Feb 2;305(5):487-94. (PMID: 21285426) Genome Res. 2014 Dec;24(12):2022-32. (PMID: 25236618) Nat Commun. 2018 Oct 5;9(1):4112. (PMID: 30291241) Eur J Cancer. 2019 Mar;109:175-182. (PMID: 30735919) J Clin Oncol. 2013 Mar 20;31(9):1219-30. (PMID: 23401453) Clin Cancer Res. 2013 Jun 1;19(11):2824-7. (PMID: 23549876) Nucleosides Nucleotides Nucleic Acids. 2006;25(9-11):1001-7. (PMID: 17065054) Stat Med. 2000 Feb 29;19(4):441-52. (PMID: 10694729) J Clin Oncol. 2015 Jan 1;33(1):22-8. (PMID: 25385741) J Clin Oncol. 2018 Jul 10;36(20):2052-2060. (PMID: 29792754) BMC Bioinformatics. 2016 Jul 25;17 Suppl 7:239. (PMID: 27454357) J Clin Oncol. 2015 Nov 10;33(32):3838-9. (PMID: 26304897) JAMA Oncol. 2019 Feb 1;5(2):236-242. (PMID: 30489611) Digestion. 2016;94(3):129-137. (PMID: 27756074) Clin Colorectal Cancer. 2018 Mar;17(1):58-64. (PMID: 29157662) BMC Cancer. 2016 Aug 24;16:677. (PMID: 27558497) Nat Rev Clin Oncol. 2009 Aug;6(8):465-77. (PMID: 19581909) Nature. 2012 Jul 18;487(7407):330-7. (PMID: 22810696) Nat Commun. 2014 Nov 14;5:5457. (PMID: 25394515) Am Health Drug Benefits. 2013 Sep;6(8):469-78. (PMID: 24991376) Ann Oncol. 2016 Aug;27(8):1386-422. (PMID: 27380959) Bioinformatics. 2009 May 1;25(9):1099-104. (PMID: 19276148) Acta Oncol. 2012 Sep;51(7):890-6. (PMID: 22974094) Int J Cancer. 2022 Oct 1;151(7):1166-1174. (PMID: 35489024) J Clin Oncol. 2009 Sep 20;27(27):4591-8. (PMID: 19704056) Sci Rep. 2017 Jul 31;7(1):6882. (PMID: 28761069) J Clin Oncol. 2021 Mar 1;39(7):861-862. (PMID: 33439690) N Engl J Med. 2009 Feb 5;360(6):563-72. (PMID: 19196673) Bioinformatics. 2007 Mar 15;23(6):657-63. (PMID: 17234643) J Clin Oncol. 2008 Apr 20;26(12):2013-9. (PMID: 18421054) Bioinformatics. 2007 Apr 1;23(7):892-4. (PMID: 17267432) Clin Transl Med. 2021 Apr;11(4):e401. (PMID: 33931971) |
| فهرسة مساهمة: | Keywords: anti-VEGF monoclonal antibody; bevacizumab; chromosome 18q; metastatic colorectal cancer; predictive biomarker; randomized controlled trial |
| المشرفين على المادة: | 2S9ZZM9Q9V (Bevacizumab) U3P01618RT (Fluorouracil) |
| تواريخ الأحداث: | Date Created: 20220430 Date Completed: 20220812 Latest Revision: 20221015 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC9545440 |
| DOI: | 10.1002/ijc.34061 |
| PMID: | 35489024 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1097-0215 |
|---|---|
| DOI: | 10.1002/ijc.34061 |